CuraSen Therapeutics has filed a notice of an exempt offering of securities to raise $45,690,305.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, CuraSen Therapeutics is raising up to $45,690,305.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Anthony Ford played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About CuraSen Therapeutics
Its time to think again about therapies for neurodegenerative disease. At CuraSen, we are targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN. CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinsons disease and Alzheimers disease, as well as several orphan indications. Millions of patients and their families are burdened by these diseases, and the numbers continue to grow annually with the aging population. At CuraSen, we are rethinking the therapeutic approach to treatment of neurodegenerative diseasesand advancing a concept based on restoring a key functionality to a pathway lost early in the degenerating brain. This pathway emanates from the locus coeruleus (LC), site of the earliest pathology seen in these diseases perhaps the hypocenter of neurodegeneration. We began clinical testing of our hypothesis in 2019 using established drugs from other therapeutic areas, which has informed our development program and helped advance our first new chemical entity, CST-2032, to the clinic in September 2020. CuraSen has assembled an impressive team, deeply experienced in the neuroscience, pharmacology and clinical development core to its approach, as well as top tier investor backing, including New Leaf Venture Partners, Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation JJDC, Inc. (JJDC), and Pappas Capital.
To learn more about CuraSen Therapeutics, visit http://www.curaseninc.com/
CuraSen Therapeutics Linkedin Page: https://www.linkedin.com/company/curasen/
Contact:
Anthony Ford, President and Chief Executive Officer
650-475-2842
https://www.linkedin.com/in/anthony-ford-676511171/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.